Evidence map›Paper›PMID 35062719›Full record

ArticleVaccines2021

A Cost-Benefit Analysis of COVID-19 Vaccination in Catalonia.

Francesc López, Martí Català, Clara Prats, Oriol Estrada, Irene Oliva, Núria Prat, Mar Isnard, Roser Vallès, Marc Vilar, Bonaventura Clotet and 3 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 4 pooled it
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Francesc LópezDirectorate for Innovation and Interdisciplinary Cooperation, North Metropolitan Territorial Authority, Catalan Institute of Health, 08006 Barcelona, Spain.ORCID 0000-0003-0977-0215
Martí CatalàComparative Medicine and Bioimage Centre of Catalonia (CMCiB), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, 08916 Barcelona, Spain.ORCID 0000-0003-3308-9905
Clara PratsComparative Medicine and Bioimage Centre of Catalonia (CMCiB), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, 08916 Barcelona, Spain.ORCID 0000-0002-1398-7559
Oriol EstradaDirectorate for Innovation and Interdisciplinary Cooperation, North Metropolitan Territorial Authority, Catalan Institute of Health, 08006 Barcelona, Spain.
Irene OlivaDirectorate for Innovation and Interdisciplinary Cooperation, North Metropolitan Territorial Authority, Catalan Institute of Health, 08006 Barcelona, Spain.
Núria PratNorth Metropolitan Primary Care Directorate, Catalan Institute of Health, 08006 Barcelona, Spain.ORCID 0000-0003-1689-9017
Mar IsnardNorth Metropolitan Primary Care Directorate, Catalan Institute of Health, 08006 Barcelona, Spain.
Roser VallèsNorth Metropolitan Primary Care Directorate, Catalan Institute of Health, 08006 Barcelona, Spain.
Marc VilarNorth Metropolitan Primary Care Directorate, Catalan Institute of Health, 08006 Barcelona, Spain.
Bonaventura ClotetFight AIDS and Infectious Diseases Foundation, 08916 Barcelona, Spain.
Josep Maria ArgimonMinistry of Health, 08007 Barcelona, Spain.
Anna AranCatalan Health Service, Ministry of Health, 08007 Barcelona, Spain.
Jordi AraDirectorate for Innovation and Interdisciplinary Cooperation, North Metropolitan Territorial Authority, Catalan Institute of Health, 08006 Barcelona, Spain.
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESMinistry of Health · ESUniversitat Pompeu Fabra · ESIrsiCaixa · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: In epidemiological terms, it has been possible to calculate the savings in health resources and the reduction in the health effects of COVID vaccines. Conducting an economic evaluation, some studies have estimated its cost-effectiveness; the vaccination shows highly favorable results, cost-saving in some cases. (2) Methods: Cost-benefit analysis of the vaccination campaign in the North Metropolitan Health Region (Catalonia). An epidemiological model based on observational data and before and after comparison is used. The information on the doses used and the assigned resources (conventional hospital beds, ICU, number of tests) was extracted from administrative data from the largest primary care provider in the region (Catalan Institute of Health). A distinction was made between the social perspective and the health system. (3) Results: the costs of vaccination are estimated at 137 million euros (€48.05/dose administered). This figure is significantly lower than the positive impacts of the vaccination campaign, which are estimated at 470 million euros (€164/dose administered). Of these, 18% corresponds to the reduction in ICU discharges, 16% to the reduction in conventional hospital discharges, 5% to the reduction in PCR tests and 1% to the reduction in RAT tests. The monetization of deaths and cases that avoid sequelae account for 53% and 5% of total savings, respectively. The benefit/cost ratio is estimated at 3.4 from a social perspective and 1.4 from a health system perspective. The social benefits of vaccination are estimated at €116.67 per vaccine dose (€19.93 from the perspective of the health system). (4) Conclusions: The mass vaccination campaign against COVID is cost-saving. From a social perspective, most of these savings come from the monetization of the reduction in mortality and cases with sequelae, although the intervention is equally widely cost-effective from the health system perspective thanks to the reduction in the use of resources. It is concluded that, from an economic perspective, the vaccination campaign has high social returns.

Indexed as

cost–benefit analysisCOVID-19economic appraisalhealth economicspharmacoeconomicsvaccination

Identifiers

PMID35062719
PMCPMC8780175
OpenAlexW4221037070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.